<DOC>
	<DOCNO>NCT00531089</DOCNO>
	<brief_summary>The general objective study assess efficacy safety Rituximab management patient refractory relapse thrombotic thrombocytopenic purpura-hemolytic uremic syndrome ( TTP-HUS ) . There several case report case series describe use Rituximab patient TTP-HUS ; however use studied large trial . It hypothesize Rituximab may ameliorate severity certain case TTP-HUS decrease number activity B-cells may result decreased production ADAMTS13 protease inhibitor . Patients TTP-HUS respond standard therapy patient relapse disease may particular benefit . Treatments decrease frequency relapse shorten time remission TTP-HUS benefit decrease need blood product support .</brief_summary>
	<brief_title>Rituximab Patients With Relapsed Refractory TTP-HUS</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Hemolysis</mesh_term>
	<mesh_term>Azotemia</mesh_term>
	<mesh_term>Hemolytic-Uremic Syndrome</mesh_term>
	<mesh_term>Purpura , Thrombotic Thrombocytopenic</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>patient 18 year old diagnose relapsed refractory TTPHUS require therapy alternate cause hemolytic microangiopathy ( evidence DIC , malignant hypertension , vasculitis , antiphospholipid antibody syndrome , postpartum acute renal failure ) congenital familial TTP TTP occur poststem cell , bone marrow , solid organ transplant druginduced TTP pregnancy breastfeed history hepatitis B C infection prior rituximab treatment active metastatic cancer cause thrombocytopenia ITP , myelodysplastic syndrome , confirm suspect druginduced thrombocytopenia refusal receive blood product hypersensitivity blood product , plasma product , murine protein , component Rituximab formulation geographic inaccessibility comorbid illness limit life expectancy le 2 month independent TTP failure provide write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>TTP</keyword>
	<keyword>thrombotic thrombocytopenic purpura</keyword>
	<keyword>HUS</keyword>
	<keyword>hemolytic uremic syndrome</keyword>
	<keyword>plasma exchange</keyword>
</DOC>